"The ongoing ROCKET program will further substantiate rocatinlimab's clinical profile by assessing disease control and ... from baseline and an Eczema Area and Severity Index score ≥75 (EASI-75), both ...
Opens in a new tab or window A literature review has confirmed that the Eczema Area and Severity Index (EASI) is an effective tool for measuring the severity and extent of atopic dermatitis (AD ...
Medpage Today on MSN15d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor"The overall safety profile was favorable ... defined as IGA ≥3, EASI ≥16, body surface area ≥10%, and weekly pruritus score ...
DURHAM, N.C. & CAMBRIDGE, Mass. & SEOUL, South Korea, March 10, 2025--Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback